14th European Congress of Clinical Microbiology and Infectious ...
14th European Congress of Clinical Microbiology and Infectious ...
14th European Congress of Clinical Microbiology and Infectious ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Poster Sessions Tuesday, May 4, 2004<br />
P1779 Identification <strong>and</strong> characterisation <strong>of</strong> clinical<br />
isolates <strong>of</strong> Trichosporon species from Kuwait<br />
S. Ahmad, M. Al-Mahmeed, Za. Khan, Zi. Khan<br />
(Safat, KWT)<br />
P1780 Phylogenetic positions <strong>of</strong> clinical isolates<br />
within the filamentous fungal genus<br />
Trichoderma<br />
L. Kredics, Z. Antal, A. Szekeres, M. Láday,<br />
I. Dóczi, J. Varga, L. Manczinger, E. Nagy<br />
(Szeged, Budapest, HUN)<br />
P1781 Growth <strong>of</strong> Aspergillus fumigatus is inhibited<br />
by C<strong>and</strong>ida species on sealed Sabouraud agar<br />
plates, but not on sealed Columbia agar<br />
plates<br />
A. Becker, N. Akkad, D.H. Forster, E. Kniehl<br />
(Karlsruhe, D)<br />
P1782 Phenotyping by Fourier-transform infrared<br />
spectroscopy versus restriction- <strong>and</strong><br />
amplification-based genotyping <strong>of</strong> C<strong>and</strong>ida<br />
tropicalis isolates: a comparison<br />
A.S. Al Masri, F. Kipp, H.C. Gugnani, W. Fegeler,<br />
K. Becker (Munster, D; Delhi, IND)<br />
P1783 Development <strong>of</strong> a lovastatin resistance-based<br />
transformation system for Rhizomucor miehei<br />
C. Vagvolgyi, G. Lukacs, I. Nyilasi, T. Papp<br />
(Szeged, HUN)<br />
P1784 Identification <strong>of</strong> Rhizomucor species by<br />
means <strong>of</strong> biochemical <strong>and</strong> molecular methods<br />
T. Papp, G. Lukacs, M. Vastag, C. Vagvolgyi,<br />
E. Nagy (Szeged, HUN)<br />
P1785 In vitro antifungal activity, cytotoxicity <strong>and</strong><br />
cellular accumulation <strong>of</strong> new water-soluble<br />
amphotericin B – polyvinylpyrrolidone<br />
formulations<br />
E. Charvalos, M.N. Tzatzarakis, F. Van Bambeke,<br />
P.M. Tulkens, A.M. Tsatsakis, M.-P. Mingeot-<br />
Leclercq (Athens, Crete, GR; Brussels, B)<br />
P1786 Two cases <strong>of</strong> severe phototoxic reactions<br />
related to long-term outpatient voriconazole<br />
treatment<br />
S.J. V<strong>and</strong>ecasteele, E. Van Wijngaerden,<br />
W.E. Peetermans (Leuven, B)<br />
P1787 Outcome <strong>and</strong> aqueous drug levels <strong>of</strong><br />
voriconazole in four patients with fungal<br />
keratitis treated with voriconazole<br />
A. Zinkernagel, M. Scherrer, J. Burhenne,<br />
W.E. Haefeli, M. Thiel (Zurich, CH; Heidelberg, D)<br />
P1788 Voriconazole for the treatment <strong>of</strong> drugresistant<br />
fungal infections: experience from<br />
a Compassionate-Use Program in Spain<br />
J.M. Aguado, J.M. Cisneros on behalf <strong>of</strong> Spanish<br />
Group <strong>of</strong> Voriconazole Study<br />
P1789 Lack <strong>of</strong> hepatic effect <strong>of</strong> anidulafungin<br />
D. Krause, J Schranz, W. Birmingham<br />
(King <strong>of</strong> Prussia, USA)<br />
P1790 Ex vivo combined activity <strong>of</strong> posaconazole<br />
<strong>and</strong> granulocyte-macrophage colonystimulating<br />
factor-treated neutrophils against<br />
Scedosporium prolificans<br />
M. Simitsopoulou, C. Gil-Lamaignere,<br />
L. Kourounaki, D. Loebenberg, E. Roilides<br />
(Thessalonica, GR; Kenilworth, USA)<br />
P1791 Posaconazole as salvage therapy for<br />
Pseudallescheria infections: a case series<br />
R. Hachem, J.R. Graybill, R. Negroni,<br />
K. Presberg, G. Schiller, P. Zakowski, L. Pedicone<br />
(Houston, San Antonio, USA; Buenos Aires,<br />
AR; Milwaukee, Los Angeles, Kenilworth, USA)<br />
13:00–14:00<br />
Progress in pharmacokinetics <strong>and</strong><br />
pharmacodynamics – II<br />
P1792 Serum protein binding <strong>of</strong> erythromycin as<br />
measured by ultrafiltration, dialysis filtration<br />
<strong>and</strong> ultracentrifugation<br />
A. S<strong>and</strong>berg, H.U. Nielsen, O. Cars,<br />
M. Christiansen, N. Frimodt-Møller<br />
(Copenhagen, DK; Uppsala, S)<br />
P1793 Pharmacokinetics <strong>of</strong> moxifloxacin in patients<br />
undergoing continuous ambulatory peritoneal<br />
dialysis<br />
C. Skalioti, T. Tsaganos, M. Raftogiannis,<br />
D. Plachouras, H. Giamarellou,<br />
E.J. Giamarellos-Bourboulis (Athens, GR)<br />
P1794 An oral regimen to achieve steady serum<br />
levels <strong>of</strong> lev<strong>of</strong>loxacin in patients undergoing<br />
hem<strong>of</strong>iltration<br />
P. Kouki, T. Tsaganos, M. Raftogiannis, P. Digenis,<br />
H. Giamarellou, E.J. Giamarellos-Bourboulis<br />
(Athens, GR)<br />
P1795 Multiple-dose pharmacokinetics <strong>of</strong> linezolid<br />
during continuous venovenous hem<strong>of</strong>iltration<br />
B. Meyer, G. Kornek, M. Nikfardjam, G. Delle Karth,<br />
G. Heinz, G. Locker, W. Jaeger, F. Thalhammer<br />
(Vienna, A)<br />
P1796 The breakpoint index – a new pharmaco -<br />
dynamic parameter for assessing antibiotic<br />
combinations<br />
I.M. Gould, K. Milne, F.M. MacKenzie<br />
(Aberdeen, UK)<br />
www.escmid.org/eccmid2004<br />
page 141
Change language